Clinical trials: Malaria, Vivax
Lung Cancer, Nonsmall Cell
Plasmodium Immunotherapy for Lung Cancer
The objective of this study is to evaluate the safety and the effectiveness of Plasmodium immunotherapy (blood-stage infection of Plasmodium vivax) for advanced non-small cell lung cancer.The treatment will last 3-6 months from…
- Trial name
- NCT02786589
- Testing
- Blood-stage infection of P. vivax
- Where
- China
- Volunteers
- 30 people
- Sponsor
- State Key Laboratory of Respiratory Disease
Malaria
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
The primary objective of this clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (180:60 mg) with that of standard chloroquine therapy in children and adults with acute…
- Trial name
- NCT04368910
- Testing
- Pyronaridine - artesunate, Chloroquine
- Where
- 2 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Medicines for Malaria Venture
Malaria Vivax
Efficacy of Chloroquine-Primaquine Treatment for Uncomplicated Plasmodium Vivax Malaria
The study was designed to evaluate the current efficacy of this combination therapy against P. vivax, given the possibility of misuse or inadequate adherence to the regimen due to its lengthy treatment duration, in one of a…
- Trial name
- CQ-PQ (NCT07753967)
- Testing
- CQ-PQ
- Where
- Ethiopia
- Volunteers
- 192 people
- Sponsor
- Jimma University
Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria
DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
This will be a Proof-of-concept / Phase IIa, open label study to examine the efficacy of DSM265 in uncomplicated Plasmodium vivax and Plasmodium falciparum blood-stage malaria in adult patients.
- Trial name
- NCT02123290
- Testing
- DSM265 400mg, DSM265 xmg, DSM265 ymg
- Where
- Peru
- Volunteers
- 45 people
- Sponsor
- Medicines for Malaria Venture
Pharmacokinetics of Tafenoquine
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07052162
- Testing
- Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat
- Where
- Papua New Guinea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Curtin University
Advanced Breast Cancer, Advanced Liver Cancer
Plasmodium Immunotherapy for Breast and Liver Cancers
The purpose of this study is to evaluate the safety and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced breast cancers and advanced liver cancers.The treatment will last 4-6 weeks from the day of…
- Trial name
- NCT03474822
- Testing
- Blood-stage infection of P.vivax
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
Malaria, Vivax, Relapse
Primaquine Double Dose for Radical Cure of Plasmodium Vivax in Colombia
Primaquine (PQ) is the only widely available treatment to prevent P. vivax relapses. World Health Organization recommends increased PQ doses in East Asia and Oceania, frequently relapsing strains.
- Trial name
- NCT05232227
- Testing
- Primaquine double dose over 14 days, Primaquine single dose over 14 days
- Sponsor
- University of California, San Francisco
Malaria, Vivax
Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria
The purpose of this study was to determine whether the proposed first line treatment for falciparum malaria in this region (sulfadoxine-pyrimethamine + artesunate) would be no worse a treatment for vivax malaria that the standard…
- Trial name
- NCT00486694
- Testing
- Sulfadoxine-pyrimethamine + artesunate, Chloroquine
- Volunteers
- 190 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Falciparum Malaria, Vivax Malaria
To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia
Multidrug resistant strains of P.falciparum and P.vivax are becoming increasingly prevalent in the Asia Pacific rim. To determine the efficacy of locally recommended antimalarial protocols in Papua, Indonesia, consecutive…
- Trial name
- NCT00157859
- Testing
- Chloroquine and sulphadoxine-pyrimethamine
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- Menzies School of Health Research
Healthy Lactating Women
Tafenoquine and Primaquine in Colostrum and Breast Milk
Each year almost a million infants are born small for gestational age due to malaria infection in pregnancy. These infants are at risk for stillbirth or neonatal death, and being born too small predisposes the survivors to…
- Trial name
- TBM (NCT04984759)
- Testing
- Primaquine, Tafenoquine
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Oxford
Vivax Malaria
Study on the Treatment of Vivax Malaria
This is a randomised open label trial with follow up for 1 year. 660 adults and children above 6 months diagnosed with acute Plasmodium vivax will be randomised into 3 groups, either chloroquine, artesunate, or…
- Trial name
- VHX (NCT01074905)
- Testing
- Artesunate, Chloroquine, Chloroquine/Primaquine
- Where
- Thailand
- Volunteers
- 655 people
- Sponsor
- University of Oxford
Malaria,Falciparum, Malaria, Vivax
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua
Comparing the efficacy of the combination treatment of bitter melon fruit extract (Momordica charantia) with primaquine (MC+PQ) against the combination of dihydroartemisinin + piperaquine + primaquine (DHP+PQ) on patients with…
- Conditions
- Malaria,Falciparum, Malaria, Vivax, Malaria, Infections
- Trial name
- MCMPFPB (NCT06036030)
- Testing
- Dihydroartemisinin, Piperaquine, Primaquine
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Syamsudin Abdillah,Ph.D, Pharm D
Malaria
Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy
This is a randomised, open label trial, comparing standard dose of dihydroartemisinin-piperaquine (DP) with standard fixed artesunate-mefloquine regimen (MAS3) and with a longer regimen of artemether-lumefantrine (ALN+) in the…
- Trial name
- DMA (NCT01054248)
- Testing
- dihydroartemisinin-piperaquine, Artesunate-mefloquine, arthemeter-lumefantrin
- Where
- Thailand
- Volunteers
- 511 people
- Sponsor
- University of Oxford
Fever, Suspected Malaria
ACT for the Home Management in Malagasy Children
The purpose of this study is to assess the feasibility, the acceptability and the effectiveness of the use of the Artesunate + Amodiaquine Fixed Dose Combination for the home management of presumed malaria in Malagasy children by…
- Trial name
- NCT00612547
- Testing
- Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- National Malaria Control Programme, Madagascar
Malaria
Malaria Studies in Cambodia
This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following…
- Trial name
- NCT00663546
- Where
- 3 sites in Cambodia
- Volunteers
- 1,978 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
The proportion of malaria that is the Plasmodium vivax species is increasing in Indonesia. Reducing vivax malaria will require innovative solutions to cure both the blood and liver stages of the disease.
- Trial name
- SCOPE (NCT05879224)
- Testing
- Revised case management package
- Where
- 6 sites in Indonesia
- Volunteers
- 2,999 people
- Sponsor
- Menzies School of Health Research
Malaria, Vivax
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.
- Trial name
- NCT05270265
- Testing
- Pvs25-IMX313/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated)
Ethiopian Antimalarial Therapeutic Efficacy Study 2026
Background: The WHO recommends monitoring the efficacy of antimalarial drugs at least once every two years after implementation.
- Trial name
- TES2026 (NCT07840898)
- Testing
- Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine
- Where
- Ethiopia
- Volunteers
- 1,200 people
- Sponsor
- Ethiopian Public Health Institute
Malaria, Plasmodium Vivax
Phase Ia Study of ChAd63/MVA PvDBP
This is an open label phase Ia study, to assess the safety of two novel malaria vaccines, ChAd63 PvDBP, with or without MVA PvDBP.
- Trial name
- NCT01816113
- Testing
- ChAd63 PvDBP 5 x 10^9, ChAd63 PvDBP 5 x 10^10, MVA PvDBP 1 x 10^8
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Malaria
Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)
The current treatment recommendations for P. vivax in pregnant and non-pregnant individuals are to use chloroquine; in non-pregnant patients this is followed by primaquine to prevent relapse.
- Trial name
- PAACT-PV (NCT01107145)
- Testing
- Mefloquine- Artesunate, Artemether-Lumefantrine, Chloroquine
- Where
- 3 sites in Brazil
- Volunteers
- 16 people
- Sponsor
- Centers for Disease Control and Prevention